Latest Articles about PSTI

PSTI Plans to Start Phase I Study - Analyst Blog

Zacks Equity Research — Sat, 20 Apr 2013 00:11:14 Z

Pluristem Therapeutics Inc. ( PSTI ) recently announced its intention to commence a phase I study that will evaluate the safety and efficacy of the local administration of PLacental

UTHR to Move PAH Drug into Phase I - Analyst Blog

Zacks Equity Research — Mon, 15 Apr 2013 20:11:40 Z

United Therapeutics Corporation ( UTHR ) recently gained approval for the commencement of a phase I study in Australia using Pluristem Therapeutics Inc. 's ( PSTI ) PLacental eXpanded

Pipeline Progress at Pluristem - Analyst Blog

Zacks Equity Research — Tue, 26 Mar 2013 02:31:03 Z

Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently reported progress on its phase I/II clinical trial, which is evaluating the safety and efficacy of its PLacental eXpanded (PLX)

Pluristem & UTHR Progress with PLX-PAD - Analyst Blog

Zacks Equity Research — Tue, 05 Mar 2013 03:25:01 Z

Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently announced that partner United Therapeutics Corporation ( UTHR ) intends to commence a phase I study in Australia using

Pluristem Progresses with New Facility - Analyst Blog

Zacks Equity Research — Sat, 05 Jan 2013 04:27:01 Z

Israel-based Pluristem Therapeutics, Inc. ( PSTI ) recently announced the initiation of the final validation steps for its new state-of-the-art manufacturing facility. Subsequent to this

Orphan Status Update from Pluristem - Analyst Blog

Zacks Equity Research — Wed, 28 Nov 2012 04:00:01 Z

Pluristem Therapeutics, Inc. ( PSTI ) recently provided an update on its efforts to gain orphan drug status for its PLacental eXpanded (PLX) cells in the treatment of aplastic anemia. The

Whatever you Do, Don't Sell This Surging Stock

David Sterman — Tue, 18 Sep 2012 22:00:00 Z

It's been roughly one month since I added shares of Celsion (Nasdaq: CLSN ) to my $100,000 Real-Money Portfolio , and they're already up nearly 25%. In fact, this stock has

Buy or Sell? Thursday's Losers: Pluristem (Nasdaq: PLSTM) and FirstMerit (Nasdaq: FMER)

David Sterman — Thu, 13 Sep 2012 17:45:00 Z

Among the biggest losers in Thursday's early trading are Pluristem (Nasdaq: PLSTM) and FirstMerit (Nasdaq: FMER). There's a very good reason why biotech investors are implored to monitor

Orphan Status Sought for PSTI Drug - Analyst Blog

Zacks Equity Research — Sat, 01 Sep 2012 01:32:48 Z

Pluristem Therapeutics, Inc. ( PSTI ) recently announced that it has filed documents with the US Food and Drug Administration (FDA) seeking orphan drug status for using its PLacental eXpanded

Pluristem to Begin IC Phase II Trial - Analyst Blog

Zacks Equity Research — Sat, 25 Aug 2012 02:30:01 Z

Pluristem Therapeutics, Inc. ( PSTI ) recently announced that it will be initiating phase II studies that will evaluate the safety and efficacy of its placental expanded (PLX) cells in

Pluristem-BCRT Alliance Extended - Analyst Blog

Zacks Equity Research — Thu, 23 Aug 2012 03:32:12 Z

Pluristem Therapeutics, Inc. ( PSTI ) recently announced the renewal of its five-year collaboration research agreement with the Berlin-Brandenburg Center for Regenerative Therapy (BCRT) at

Pluristem Gets Green Light in India - Analyst Blog

Zacks Equity Research — Tue, 21 Aug 2012 03:32:06 Z

Pluristem Therapeutics, Inc. ( PSTI ) recently announced that the Indian Ministry of Health has given the company permission to conduct a phase II clinical trial for the treatment of

6 Biotech Penny Stocks to Buy

Louis Navellier — Fri, 24 Jun 2011 10:00:42 Z

Just What the Doctor Ordered Health care is considered a defensive sector, and large-cap health-care stocks tend to outperform in times of economic uncertainty and stock market turmoil.